You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 17, 2025

CLINICAL TRIALS PROFILE FOR ROTIGOTINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Rotigotine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00135993 ↗ Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome Completed UCB Pharma Phase 3 2005-05-01 Subjects who meet the diagnosis of idiopathic restless legs syndrome (RLS) based on the 4 cardinal clinical features according to the International Restless Legs Syndrome Study Group (IRLSSG) are allowed to enroll in this trial. The primary objective of this trial is to demonstrate that rotigotine (SPM 936) is efficacious in subjects with idiopathic restless legs syndrome. Additional objectives are to investigate the safety and tolerability of rotigotine. Subjects will be randomized to receive either placebo, 1.125, 2.25, 4.5, or 6.75mg/day rotigotine in a 1:1:1:1:1 (active:placebo) fashion. Approximately 600 subjects will be enrolled in this trial, participating at approximately 60 sites. The maximum duration of the trial is approximately 8 months (consisting of a 4-week Titration Period, a 6-month Maintenance Period, a 7-day Taper Period, and a 30-day Safety Follow-Up Period).
NCT00136045 ↗ Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome Completed UCB Pharma Phase 3 2005-05-01 The primary objective of this trial is to demonstrate that rotigotine (SPM 936) is efficacious in subjects with idiopathic restless leg syndrome (RLS). Additional objectives are to investigate the safety and tolerability of rotigotine. The primary variables are the absolute change from Baseline in the International Restless Legs Severity Scale (IRLS) sum score and Clinical Global Impression-Global Improvement (CGI) Item 1 (severity of illness) score at the end of the Maintenance Period. Subjects will be randomized to receive either placebo, 2.25, 4.5 or 6.75 mg/day rotigotine in a 1:1:1:1 (active:placebo) fashion. Approximately 450 subjects will be enrolled in this trial, participating at approximately 50 sites. The maximum duration of the trial is approximately 8 months (3-week Titration Period, 6-month Maintenance Period, 7-day Taper Period, and 30-day Safety Follow-Up Period). Subjects who complete the 6-month Maintenance Period will be eligible to participate in an open-label extension trial. Subjects who do not complete the 6-month Maintenance Period or who choose not to participate in the open-label extension trial will complete a 3-day Safety Follow-Up Period. Two different patch sizes will be used (5 and 10 cm2). Active patches will contain either 2.25mg (5cm2) or 4.5mg (10cm2) of rotigotine.
NCT00242008 ↗ A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease Completed UCB Pharma Phase 3 2004-12-01 The purpose of this trial is to assess whether it is possible for subjects with idiopathic Parkinson's Disease to switch from ropinirole, pramipexole and cabergoline to rotigotine transdermal system (SPM 962) overnight without worsening of Parkinson's Disease symptoms. Subjects who meet eligibility criteria will be switched overnight to treatment with rotigotine transdermal patches at a dose considered equivalent to the dose of dopamine agonist that the subject is currently taking. Subjects on ropinirole or pramipexole will take their last dose at bedtime and then apply rotigotine patch(es) upon awakening the next morning. Subjects on cabergoline will apply rotigotine patches 24 hours after the final dose of cabergoline. Subjects will continue rotigotine treatment for 28 days, during which dose can be increased or decreased as needed. At the end of treatment, subjects can select to enroll in an open-label extension trial. The first subject was enrolled on 28 December 2004. The last subject was enrolled in June 2005 and the last subject visit was conducted in July 2005. This study is now closed.
NCT00243217 ↗ Rotigotine Restless Legs Syndrome Dose Finding Trial Completed UCB Pharma Phase 2 2003-04-01 The objective of this trial is to demonstrate clinical efficacy of four different dosages of SPM 962 1.125 mg, 2.25 mg, 4.5 mg and 6.75 mg (corresponding to 2.5 cm2, 5 cm2, 10 cm2 and 15 cm2 patch size respectively) in RLS subjects. It is anticipated that rotigotine (SPM 936) will be more effective than placebo. The tolerability and safety of rotigotine will be assessed.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Rotigotine

Condition Name

Condition Name for Rotigotine
Intervention Trials
Parkinson's Disease 22
Restless Legs Syndrome 14
Idiopathic Parkinson's Disease 8
Parkinson Disease 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Rotigotine
Intervention Trials
Parkinson Disease 46
Syndrome 20
Restless Legs Syndrome 19
Psychomotor Agitation 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Rotigotine

Trials by Country

Trials by Country for Rotigotine
Location Trials
United States 253
Germany 29
Italy 16
Spain 9
Canada 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Rotigotine
Location Trials
Florida 22
California 17
North Carolina 16
Texas 13
New York 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Rotigotine

Clinical Trial Phase

Clinical Trial Phase for Rotigotine
Clinical Trial Phase Trials
Phase 4 11
Phase 3 29
Phase 2/Phase 3 1
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Rotigotine
Clinical Trial Phase Trials
Completed 66
Terminated 5
Unknown status 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Rotigotine

Sponsor Name

Sponsor Name for Rotigotine
Sponsor Trials
UCB Pharma 40
UCB BIOSCIENCES GmbH 9
Otsuka Pharmaceutical Co., Ltd. 8
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Rotigotine
Sponsor Trials
Industry 72
Other 21
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Rotigotine: Clinical Trials, Market Analysis, and Projections

Introduction to Rotigotine

Rotigotine is a non-ergoline dopamine agonist approved for the treatment of Parkinson’s disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch to enhance bioavailability and provide a steady supply of the drug over 24 hours[3].

Clinical Trials and Efficacy

Meta-Analysis and Clinical Outcomes

A meta-analysis of six randomized controlled trials involving 1789 patients showed that rotigotine significantly improved symptoms of Parkinson’s disease. The Unified Parkinson’s Disease Rating Scale (UPDRS) scores indicated greater improvements in activities of daily living, motor scores, and the combined activities of daily living and motor subtotal scores compared to placebo. However, rotigotine was associated with a higher incidence of adverse events and withdrawals due to these events[1].

Ongoing and Planned Clinical Trials

BioNxt Solutions Inc. is preparing for a human clinical pilot study in Q2 2023 to assess the relative bioavailability, skin adhesion, and skin tolerance of their new optimized transdermal formulation of rotigotine compared to the existing name brand product. This study will be conducted in Europe, following Good Clinical Practice (GCP) and European Medical Agency (EMA) guidelines[2].

Another clinical trial aims to investigate the patch adhesion properties of a newly developed rotigotine patch and the marketed Neupro® 8 mg/24 h patch. This multi-centre, open, randomized trial will evaluate patch adhesion after multiple applications in patients with idiopathic Parkinson’s disease[5].

Market Analysis

Global Market Size and Growth

The global market for rotigotine patches is substantial and growing. In 2021, total global sales for rotigotine patches were approximately $518 million, with the market expected to surpass $766 million by 2030[3].

Transdermal Skin Patch Market

The broader transdermal skin patch market had a value of nearly $6.5 billion in 2020 and is projected to reach approximately $20 billion by 2028. This growth indicates a strong demand for transdermal delivery systems, which rotigotine patches are a part of[3].

Therapeutic Market for Parkinson’s Disease

The therapeutic market for Parkinson’s disease is significant, with over 10 million people worldwide affected and the number growing. This demographic trend supports the continued demand for effective treatments like rotigotine[3].

Commercialization and Market Projections

BioNxt Solutions Inc.

BioNxt Solutions Inc. has reported excellent in-vitro/ex-vivo results for their new optimized transdermal formulation of rotigotine. The company is leveraging its TDS platform technology to enhance drug absorption and skin adhesion. With positive results, BioNxt is moving forward with clinical trials and commercialization plans, which could further expand the market share of rotigotine patches[2].

XPhyto Therapeutics

XPhyto Therapeutics has also reported excellent in-vitro/ex-vivo results for their rotigotine transdermal product. Their platform technology represents a scalable opportunity for additional TDS drug development and manufacturing programs, potentially increasing the market presence of rotigotine patches[3].

Safety and Adverse Events

Adverse Events in Clinical Trials

Clinical trials have shown that rotigotine is associated with a higher rate of withdrawals due to adverse events compared to placebo. Common adverse events include those related to the gastrointestinal system, nervous system, and skin reactions. Despite these side effects, the overall efficacy of rotigotine in managing Parkinson’s disease symptoms is well-documented[1][4].

Future Outlook

Market Growth Potential

The market for rotigotine patches is expected to continue growing, driven by the increasing prevalence of Parkinson’s disease and the preference for transdermal delivery systems. The projected growth to over $766 million by 2030 underscores the potential for rotigotine to remain a significant player in the treatment of PD and RLS[3].

Technological Advancements

Advancements in transdermal patch technology, such as those being developed by BioNxt and XPhyto, are likely to improve the bioavailability, skin adhesion, and overall patient compliance with rotigotine treatment. These improvements could further enhance the market position of rotigotine patches[2][3].

Key Takeaways

  • Efficacy: Rotigotine significantly improves Parkinson’s disease symptoms, as evidenced by clinical trials and meta-analyses.
  • Market Size: The global market for rotigotine patches was approximately $518 million in 2021 and is projected to surpass $766 million by 2030.
  • Transdermal Market: The broader transdermal skin patch market is growing, expected to reach $20 billion by 2028.
  • Commercialization: Companies like BioNxt and XPhyto are advancing the technology and commercialization of rotigotine patches.
  • Safety: While effective, rotigotine is associated with a higher rate of adverse events and withdrawals compared to placebo.

FAQs

Q: What is rotigotine used for?

A: Rotigotine is used for the treatment of Parkinson’s disease and restless legs syndrome (RLS).

Q: How is rotigotine administered?

A: Rotigotine is administered via a once-daily transdermal patch to enhance bioavailability and provide a steady supply of the drug over 24 hours.

Q: What are the common adverse events associated with rotigotine?

A: Common adverse events include gastrointestinal issues, nervous system reactions, and skin reactions.

Q: What is the current market size for rotigotine patches?

A: The global sales for rotigotine patches were approximately $518 million in 2021.

Q: What are the projected market growth and future outlook for rotigotine patches?

A: The market is expected to surpass $766 million by 2030, driven by the increasing prevalence of Parkinson’s disease and advancements in transdermal patch technology.

Sources

  1. PLOS ONE: "Rotigotine Transdermal Patch in Parkinson's Disease"
  2. BioSpace: "BioNxt Reports Update on Commercialization of Rotigotine Patch for Treatment of Parkinson’s Disease"
  3. BioSpace: "XPhyto Reports Excellent Rotigotine In-Vitro/Ex-Vivo Results for Parkinson’s Disease Treatment"
  4. FDA: "Neupro (Rotigotine) patch transdermal system"
  5. Veeva: "Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients with Parkinson’s Disease"

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.